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Context:We studied two sisters with congenital hypothyroidism and
choreoathetosis but not respiratory distress.
Objective: The aim of this study was to establish the genetic defect
that causes this phenotype and study the molecular mechanisms of
the pathology by means of functional analysis.
Design: Sequencing of DNA, expression vectors generation, EMSAs,
transfections experiments as well as bioinformatics analysis were
performed.
Results:We found a new single deletion (825delC) in one allele of the
TITF1/NKX2.1 gene. The mutation located in the C-terminal domain
generates a nonsense thyroid transcription factor 1 (TTF1) protein,
with 22 amino less and rich in positive charges. This protein shows
diminished binding to DNA, does not interfere with wild-type (wt)
TTF1 binding, and fails to activate reporter genes harboring the
thyroglobulin (Tg), thyroperoxidase (TPO), or surfactant protein B
(SP-B) promoters. In addition, the mutant (mut) protein has a dom-
inant-negative effect on the transcriptional activity of wt TTF1 in a
promoter-specific manner, inhibiting the transcription of Tg and TPO
but not of SP-B. Using a Gal4 reporter system, we demonstrate that
the mut protein is not transcriptionally active and does not likely
compete with the wild type for coactivators. Interestingly, the mut
protein impairs the wt capacity to synergize with paired box 8 (PAX8).
This cooperation is necessary for Tg and TPO transcription but dis-
pensable for SP-B expression.
Conclusion: These results are concordant with the phenotype of the
two sisters studied and demonstrate a differential role for TTF1 in the
different tissues in which it is expressed. (JClin EndocrinolMetab
91: 1832–1841, 2006)
NEUROLOGICAL SYMPTOMS AND maturation delayin newborns with congenital hypothyroidism (CH)
have been attributed to thyroid hormone deficiency in the
developing brain. Neonatal screening programs for CH,
early diagnosis, and appropriate treatment permit normal
progression for most CH patients, whereas unfavorable out-
come is considered to be due to late diagnosis and/or in-
adequate treatment. In rare cases, however, neurological out-
come is poor, even after adequate hormone replacement; in
these patients, retardation of psychomotor developmentmay
be related to other defects, such as an underlying genetic
condition. Mutations in the paired box 8 (PAX8) (1–5) and
forkhead FOXE1 [formerly called TTF2 (thyroid transcrip-
tion factor 2)] (6, 7) genes have been associated with thyroid
dysgenesis but never neurological diseases. Recently several
cases of neurological problems associated with thyroid ab-
normalities that are due to mutations in the thyroid tran-
scription factor 1 (TITF1/NKX2.1) (8–14) and the monocar-
boxylate transporter (MCT8) (15, 16) have been described.
TITF1/NKX2.1 [formerly termed TTF1 (thyroid transcrip-
tion factor 1) or thyroid/enhancer binding protein] is amem-
ber of the NK-2 gene family of transcription factors (17),
which was first identified as a nuclear protein able to bind
a specific sequence in the thyroglobulin (Tg) gene promoter
(18, 19). TITF1/NKX2.1 expression is not restricted to the
thyroid because it has also been observed in forebrain and
lung during embryogenesis (20, 21). Developmental defects
of these structureswere described in nullTITF1/NKX2.1mice
characterized by thyroid agenesis, transformation of hypo-
thalamus pallidum to striatum, and lung hypoplasia with
severe respiratory failure, which is responsible for lethality
at birth (22, 23). Based on the thyroid dysgenesis phenotype
of the null mice, human TITF1/NKX2.1 was postulated as a
candidate gene for CH, although no mutations have been
found so far in patients with a phenotype restricted to thy-
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roid dysgenesis (24–26). In contrast, several patients with
chromosomal deletions (8, 9, 11, 12) and point mutations in
this gene (10–14) had a complex phenotype that included
thyroid, respiratory, and neurological defects, with benign
hereditary chorea (BHC) being the most frequent among the
neurological problems. This autosomal dominant disease is
defined by rapid involuntary and slow writhing movements
due to defects in the basal ganglia, a brain region in which
TTF1 is expressed during development. Moreover, the BHC
is linked to a region on chromosome 14 that includes the
TITF1/NKX2.1 gene (27) and is normally associatedwithmild
or severe hypothyroidism and, in most cases, respiratory
problems.
Here we report two sisters, detected in a screening for CH,
that present mild hypothyroidism in addition to choreoath-
etosis but no respiratory distress. We found a deletion of
cytosine 825 (825delC) in exon 3 in one allele of TITF1/
NKX2.1 gene; functional studies showed that the mutated
nonsense protein can act in a dominant negative fashion,
impairing the transcriptional activity of the wild-type (wt)
TTF1 by inhibiting its cooperation with PAX8.
Patients and Methods
Patients
Case 1. She had a birth weight of 4300 g, birth length of 52 cm, and Apgar
score 7/10. The neonatal screening data determined at postnatal d 18
were TSH of 186.2 mU/liter (upper reference value, 16.9 mU/liter) and
T4 of 6.5 g/dl (lower reference value, 9.6 g/dl). Thyroid scintigraphy
revealed a normotopic, bilobulated gland with low uptake. Transient
hypothyroidism was initially suspected. Treatment was finally begun
based on the high levels of TSH and low-normal T4 values, which
normalized with low doses of levothyroxine (6–8 g/d). Doses in-
creased with age and at the age of 11 yr, 100 g/d were required. At 15
months, the child did not walk and choreoathetotic movements that
hindered psychomotor progression appeared. Slight psychomotor delay
also became evident at that age.
Case 2. A sister was born 6 yr later (birth weight, 4330 g; birth length,
50 cm) with similar biochemical characteristics. The neonatal screening
data determined at postnatal d 17 were TSH of 65.0 mU/liter (upper
reference value, 14.3 mU/liter) and T4 of 9.7 g/dl (lower reference
value, 21.2 g/dl). Treatment was begun at 2 months of age, when TSH
values remained high and T4 values declined. Scintigraphy and follow-
up, with the appearance of choreoathetotic movements, mirrored her
sister’s history. No pulmonary involvement was observed in either case.
Brain magnetic resonance imaging performed at age 7 yr in case 1 and
at age 4 yr in case 2 was normal.
In view of this second case, a detailed family historywas taken, which
revealed that the mother had had transient hypothyroidism during both
pregnancies and that the maternal grandmother had suffered a mild
form of chorea with no lifelong mental impairment, but no records of
hypothyroidism were found. The mother currently has TSH levels of
10–12 mU/liter and normal T4 and free T4 values and bears the same
deletion as her daughters. The choreoathetosis history of the grand-
mother was reported by the family, but no mutational study was per-
formed (Fig. 1). In all cases, study protocols were approved by the Vall
d’Hebron Hospital Institutional Review Board committee.
Psychomotor evaluation
Tests used were the Denver developmental test (18 months of age,
case 2); theMcCarthy cognitive test, Luria’s neuropsychological test and
projective emotional tests (4 yr of age, cases 1 and 2), and the Wechsler
Intelligence Scale for Children-Revised test (5, 8, and 11 yr, case 1).
Mutational analysis
Genetic analyses were performed after informed consent of all indi-
viduals studied and approved by the institutional review board com-
mittee. Genomic DNA of the subjects was extracted from peripheral
blood leukocytes according to the manufacturer’s instructions (Nucleo-
Spin Blood; CLONTECH, Madrid, Spain). The three coding exons of the
TITF1/NKX2.1 gene were amplified using sequences and conditions
kindly provided byDr. Samuel Refetoff (University of Chicago, Chicago,
IL), sequenced in both directions (sense and antisense) and loaded onto
an ABI PRISM 3100 Avant DNA sequencer (Applied Biosystems, Ma-
drid, Spain).
Plasmids
Plasmids used in this work were human cDNA wt TTF1 and Pax8
cloned in pcDNA3 (10, 28) and reporter vectors, hTGenh/prom-Luc and
hTPOprom-Luc cloned in pGL3 Basic (5, 10) and hSP-Bprom-Luc (B-500)
cloned in pGL2 Basic (29); pG5-luciferase reporter plasmid has five
copies of Gal4 DNA binding sites (30), and pM2 vector contains the
DNA-binding domain of Gal4.
Site-directed mutagenesis
The human mut TTF1 (825delC) was generated by site-directed mu-
tagenesis using asymmetric PCR and a single mutated primer (31, 32).
The method involves two steps: the first PCR uses the mutant (mut)
oligonucleotide containing the described mutation (reverse primer mut:
5-GCGCCCGGCGCGGGGCACCCGCC-3; thewt sequence has five
G’s in the underlined region) and a nearby flanking primer (forward
primer: 5-GGG GGC GGC GGG GGC ACC GGG-3). The resulting
product (127 bp) together with reverse primer II (5-GAG GGC GGT
CGC CGC TGA GCC-3) was then used in a second round of PCR. The
amplifications were performed with 5–50 fmol of plasmid (pcDNA3 wt
TTF1) in 50 l containing 10 buffer Pfu Turbo, 10 mm deoxynucleotide
triphosphate, 10 pmol 5-flanking primer, 10 pmol antisense mut primer
(in second PCR, 20 pmol amplified mut fragment were used), and 1 U
Pfu Turbo polymerase (Stratagene, Madrid, Spain). Amplification was
done with an annealing temperature of 68 C for 40 cycles and 10 min of
final extension. Products of the second PCR (990 bp) and pcDNA3 wt
TTF1were digestedwith BlpI. After each step, PCR products and vectors
were purified by gel electrophoresis and the GFX PCR DNA and gel
band purification kit (Amersham Biosciences, Barcelona, Spain), accord-
ing to the manufacturer’s protocols. The pcDNA3 fragment was de-
phosphorylated, and both DNAs were ligated to generate pcDNA3 mut
TTF1. The vector with the deletion (825delC) was sequenced to confirm
the presence of the mutation (Fig. 2C).
FIG. 1. Family pedigree showing the autosomal dominant inheri-
tance pattern with variable clinical expression of the mut TITF1/
NKX2.1 allele in carriers. The mother and her daughters are het-
erozygous carriers of the 825delC mutation; although the
grandmother is dead, the symptoms described by the family suggest
that she also carried the mutation. Black symbols represent hypo-
thyroidism with BHC. The half-black symbol (left) represents BHC
and (right) mild hypothyroidism. Open symbols indicate unaffected
individuals. A question mark denotes uncertain diagnosis. Arrows
indicate the index patients.
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Generation of Gal4 constructs
The Gal4-wt TTF1 and Gal4-mut TTF1 chimeras were constructed in
the plasmid pM2. The TTF1 wt and mut cDNAs were obtained by PCR
from the expression vectors generated above using two primers with
specific restriction sites to allow subcloning into the BamHI and HindIII
sites of pM2 (forward primer: 5-cgc cgg aat tcc gga tcc TCG ATG AGT
CCAAAG CAC AC-3; reverse primer: 5-ac tta tct aga caa gct tTC TCA
CCA GGT CCG ACC GTA T-3, TTF1 sequence are in capital letters). All
steps were performed under the same conditions as the PCR for site-
directedmutagenesis. Sequencing of the generated constructs confirmed
that they correspond to the wt and mut TTF1 cDNAs, respectively.
In vitro synthesis of TTF1 and EMSA
Proteins were synthesized from wt and mut TTF1 vectors by in vitro
transcription/translation using the TNT coupled reticulocyte lysate sys-
tem (Promega, Madrid, Spain). For EMSAs, the in vitro-translated pro-
teins were mixed with 32P-labeled oligonucleotide C (33), C (34), or
surfactant protein B (SP-B)-f1 (35) derived from the Tg, thyroperoxidase
(TPO), and SP-B promoters, respectively, were performed as previously
described (33). In supershift experiments, an excess of related anti-TTF1
(BioPat, PiedimonteMatese, Italy) or unrelated anti-specificity protein-1
(Sp1) (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were
added before probe addition.
In vitro transactivation assay
HeLa cells were transfected as previously described (33) with 3 g
reporter plasmid DNA per dish and different amounts of wt, mut, and
empty/carrier vector, as indicated in each experiment. To correct for
transfection efficiency, 50 ng of Renilla-encoding pRL-Tk vector was
added in all cases. After 48 h, cells were harvested, lysed, and analyzed
for luciferase (LUC) and Renilla activity using the dual-LUC reporter
assay system (Promega). The ratio between the LUC and Renilla activ-
ities was expressed relative to the ratio obtained in cells transfected with
reporter and empty expression vector (pcDNA3) only.
Analysis of TTF1 protein
Aliquots of in vitro-transcribed/translated protein or 25 g of total
extracts from transfected HeLa cells, quantified according to Bradford
(Bio-Rad Laboratories, Madrid, Spain), were separated by 10% SDS-
PAGE and transferred to nitrocellulose membranes (Schleicher &
Schuell, Dassel, Germany). Ponceau S staining showed equal protein
loading. Membranes were blocked and incubated with anti-TTF1 anti-
body (BioPat). Immunoreactive bands were visualized with Luminol
Western blot detection reagent (Santa Cruz).
Bioinformatic analysis
Results were analyzed using the DNASTAR (DNASTAR, Inc., Uni-
versity of California, San Francisco, CA), nucleotide BLAST (http://
FIG. 2. Identification of the mutation in the TITF1/NKX2.1 gene and amino acid sequence of the wt and mut TTF1 proteins. Fragments of
sequence chromatograms from an unaffected individual (A), a patient (B), and the vector construct harboring the mutation (C). The arrow
indicates deletion of a cytosine at position 825 of the TITF1/NKX2.1 cDNA (position 1 is the first coding nucleotide in exon 2). The heterozygous
mutation produces a double sequence beyond the deletion site. The encoded amino acids in wt and mut TTF1 are indicated. D, Amino acid
sequence comparison of wt and mut (bold) TTF1 proteins, deduced by bioinformatics programs. The homeobox (gray box), glutamine/alanine-rich
regions (blue), cysteines for dimerization (green), and serines involved in phosphorylation (red) are shown. The positively charged amino acids
in the nonsense region of mut TTF1 are in a black box and are indicated with . Important amino acids absent from the mutated protein are
indicated in the wt protein with the colors blue, green, and red having the same meaning as indicated above.
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www.ncbi.nlm.nih.gov/BLAST),andExPASyproteomicsserver (http://
www.expasy.org/) tools and software programs. Prediction of secondary
structurewasperformedbySOPMA(36) (http://npsa-pbil.ibcp.fr/cgi-bin/
npsa_automat.pl?pagenpsa_sopma.html).
Statistical analysis
Statistical comparisons were done using Student’s paired t test, and
the significance was set at P  0.05.
Results
Psychomotor evaluation
Case 1. In the first evaluation at the age of 5 yr, notably poor
motor skills were observed, particularly in balance and gross
motor scale. Comparative study of the Wechsler Intelligence
Scale for Children-Revised tests at ages 5, 8, and 11 yr re-
vealed a slight decline in verbal scale and an even slighter
decline in manipulative skills but always within the normal
range. Comparison of parameters for attention,memory, and
motility in the Luria test showed slight memory and atten-
tion deficits in each evaluation.
Case 2. At the age of 4 yr, loss of balance, tremor, hyper-
reflexia, and mental retardation were observed in the
McCarthy test, with a marked decline in verbal performance
and motor skills. Both were below the normal range.
The family pedigree is shown in Fig. 1, and the two pa-
tients studied are indicated by an arrow.
Mutation analysis
Sequencing analysis of the three coding exons of theTITF1/
NKX2.1 gene in both patients (Fig. 2B) revealed a hetero-
zygous deletion of a cytosine (C) in the third exon, affect-
ing nucleotide 825 (825delC; GenBank accession no.
NM_003317). This mutation generates a frameshift and a
nonsense protein that lacks the correct transactivation do-
main in the C-terminal region (30). The frameshift occurs at
codon 275, resulting in an aberrant protein starting at codon
276 because proline 275 was unaltered. It extends 74 amino
acids and finishes at a premature stop at codon 350, pro-
ducing a protein that lacks 22 amino acids, compared with
the wt protein (Fig. 2D). Genetic analysis of the family
showed that the mother also carried the mutation (data not
shown).
The normal and mutated TITF1/NKX2.1 gene, generated
by site-directed mutagenesis (Fig. 2C), were expressed in
TNT and analyzed by SDS-PAGE andWestern blotting (Fig.
3A). Although the predicted molecular weight for the mu-
tated protein is lower than for thewt, the size observed in the
gel was slightly higher. We interpret this difference as being
due to the generation in themutated protein of 20 new amino
acids with a strong (43%) increase in positive charge because
of the lysine- and arginine-rich nonsense region, resulting in
a protein with a slightly slower electrophoretic mobility than
the wt form. When both wt and mut TTF1 are expressed, a
weaker band of a lower molecular weight appears that cor-
responds to a product translated from a downstream ATG,
as described elsewhere (37, 38). The protein generated is
recognized in Western blots by anti-TTF1 antibody, indicat-
ing that the mutated protein conserves immunological prop-
erties of thewt. The C-terminal region of themutated protein
has lost the glutamine/alanine-rich third domain, which has
been described as necessary for TTF1 transactivation (30).
Two serines (S327 and S336) involved in TTF1 phosphory-
lation (39) and a cysteine (C362) required for TTF1 dimer-
ization (40) are also absent (Figs. 2D and 3B). The same
apparent molecular weight was observed when the protein
was expressed in eukaryotic HeLa cells (data not shown).
DNA binding capacity of mutated and wt TTF1 proteins
To characterize the mechanism by which the 825delC de-
letion causes disease,we studied the ability of themut to bind
DNA.Weused oligonucleotides derived from the TTF1 bind-
ing siteswithin the Tg (oligoC), TPO (oligoC), or SP-B (oligo
SPB-f1) promoters. Although the deletion is outside the
DNA-binding domain, themut protein has a greatly reduced
ability to bind to its binding site in the Tg (Fig. 4A, lanes 7
and 8), TPO (Fig. 4B, lane 5), and SP-B (Fig. 4C, lanes 7 and
8) promoters. The mutated TTF1/DNA complex appears as
a diffuse band, less retarded thanwt; it is nonetheless specific
because binding is abolished by an excess of the related
oligonucleotide (Fig. 4A, lane 10; 4B, lane 6; and 4C, lane 9)
FIG. 3. Western blot analysis and schematic representation of TTF1.
A, Plasmid DNA (1g) containing wt TTF1 or mut TTF1 cDNA served
as a template in a coupled transcription/translation reaction in the
TNT system. The in vitro translation products (2 l) were analyzed
by Western blotting. Molecular weight standards are indicated at the
left and the corresponding size of wt and mut TTF1 at the right. Both
proteins were recognized by an anti-TTF1 antibody. The mutated
protein migrates more slowly than wt TTF1, despite having 22 amino
acids less. A weaker band of a lower-molecular-weight protein rep-
resents a product translated from a downstream ATG, as described
(37, 38). B, Schematic representation of wt and mut TTF1 proteins
showing the most important regions for activity, using the color code
described in Fig. 2D. The theoretical molecular weight (MW), iso-
electric point (pI), and total and charged amino acids are indicated.
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FIG. 4. DNA-binding activity of the mutated TTF1 protein. A, wt or mut TTF1 proteins translated from TNT reticulocytes were incubated alone
(lanes 3–6 and 7–10, respectively) or in combination (lanes 11–14) with the C oligonucleotide derived from the Tg promoter. Empty pcDNA3
vector was used as control (lane 2). For competition, a 100-fold excess of unrelated Sp1 (lanes 5, 9, 13) or related C (lanes 6, 10, 14) oligonucleotides
were used. The amount of lysate (in microliters) added to each lane is indicated at the top of the figure. B, EMSA with wt or mut TTF1 protein
translated from TNT reticulocytes (lanes 3 and 4 and 5 and 6, respectively) and the oligonucleotide C derived from the TPO promoter. pcDNA3
was used as control (lane 2). For competition, a 100-fold excess of oligo C (lanes 4 and 6) was used. The amount of lysate (in microliters) added
to each lane is indicated at the top. C, wt or mut TTF1 proteins translated from TNT reticulocytes were incubated alone (lanes 4–6 and 7–9,
respectively) or in combination (lanes 10–12) with the SPB-f1 oligonucleotide derived from the SP-B promoter. Empty pcDNA3 vector was used
as control (lanes 2 and 3). For competition, a 100-fold excess of related SPB-f1 (lanes 3, 6, 9, and 12) oligonucleotides were used. The amount
of lysate (microliters) added to each lane is indicated at the top. Note that the band of the wt TTF1/DNA complex migrates to the same position
as the nonspecific band but that the TTF1 band is competed by the specific competitor and the unspecific band is not.
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but not an unrelated oligonucleotide (Fig. 4A, lane 9). Spec-
ificity of binding by the wt protein was confirmed in com-
petition experiments (Fig. 4A, lane 6; 4B, lane 4; and 4C, lane
6). Equal amounts of mutated TTF1 protein did not interfere
with wt TTF1 binding (Fig. 4A, lane 11; and 4C, lane 10).
When we used a 2.5-fold excess of mutated protein, we
observed slight interference with wt TTF1-Tg oligo C com-
plex formation (Fig. 4A, lane 12) but not withwt TTF1-SPB-f1
complex formation (Fig. 4C, lane 11). The interference ob-
served in a representative EMSA (Fig. 4A, lane 12) was cal-
culated as a percentage of the wt retarded band intensity in
four independent experiments; statistical analysis indicated
that the decrease is not significant (data not shown).
Supershift experiments using a specific anti-TTF1 anti-
body showed that the protein/DNA complexes observed
with oligo C or SPB-f1 probes contain the TTF1 moiety (Fig.
5, A and B, lanes 4, 7, and 10). Supershift specificity was
demonstrated using an unrelated anti-Sp1 antibody (Fig. 5,
A and B, lanes 5, 8, and 11). The supershifts generated by the
mutated TTF1 protein were very weak (Fig. 5, A and B, lane
7) due to its extremely low DNA binding ability. When wt
and mutated proteins were combined, the supershift ob-
tainedwas equal to that observedwithwt alone (Fig. 5, A and
B, lane 10). In addition, the supershift complexwas displaced
by an excess of unlabeled oligonucleotide (Fig. 5, A and B,
lane 12). Taken together, the data show that in the heterozy-
gous patients the mut TTF1 does not interfere with the DNA
binding of the wt.
Transactivation capacity of mutated and wt TTF1 proteins
Therefore, we studied the transactivation activity of the
mutated protein because the mutation occurs in one of the
two transactivation domains (30). Themutated protein failed
to transactivate transcription from reporters harboring the
human Tg enhancer/promoter (Fig. 6A), the human TPO
promoter (Fig. 6B), or the human SP-B promoter (Fig. 6C).
The mutated protein interfered with the transcriptional ac-
tivity of wt TTF1 protein only when we used the Tg enhanc-
er/promoter (Fig. 6A) or the TPO promoter (Fig. 6B), but did
not interferewith transcription from the SP-B promoter, even
with increased amounts of mutated protein (Fig. 6C). The Tg
promoter was most affected because equal amounts of both
proteins decreased Tg transcription to 15–20%; the domi-
nant-negative effect was less pronounced for TPO (50–55%
decrease). These data suggest that the mutated TTF1 protein
acts in a dominant-negative way and a promoter-specific
manner, possibly due to competition for available activators
or coactivators.
To further understand the dominant-negative action and
investigate whether mut TTF1 intrinsically binds coactiva-
tors, we generated a Gal4 fusion protein (41) harboring the
wt or mut TTF1. We found that the wt protein is able to
activate the transcription of a reporter vector containing 5
Gal4-binding domain (pG5), whereas the mut has lost this
activity and represses in part the activity of the wt (Fig. 7A,
gray bars). Thus, competition for coactivators does not seem
to explain the mechanism of action of mutated TTF1. To look
more closely at the dominant-negative effect of mut TTF1, a
vector expressing human PAX8was cotransfected. This tran-
scription factor is expressed in thyroid but not in lung and
synergizes with TTF1 to stimulate Tg and TPO promoter
activities (42).We found that PAX8 synergizedwithwt TTF1,
increasing Tg promoter activity but failed to increase the
activity of mutated protein. Interestingly, the mutated TTF1
protein interferes with the capacity of the wt to cooperate
with PAX8, decreasing the levels of activation (Fig. 7B, black
bars). These results were reproduced in the Gal4 system, in
FIG. 5. The mutated TTF1/DNA complex is recognized by an anti-
TTF1 antibody. wt or mut TTF1 proteins translated from TNT re-
ticulocytes were incubated alone (lanes 3–5 and 6–8, respectively) or
in combination (lanes 9–12) with the Tg C site (A) or the SPB-f1
element (B), as described in the legend to Fig. 4. A clear supershift was
observed when an anti-TTF1 antibody was added to the binding
reaction (lanes 4, 7, and 10, both panels) but not when an unrelated
anti-Sp1 antibody was added (lanes 5, 8, and 11, both panels). The
specificity of the shift and supershift complexes was demonstrated by
competition with an excess of related oligonucleotide (lane 12, both
panels).
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which mutated protein diminished the TTF1/PAX8 cooper-
ation to almost undetectable levels (Fig. 7A, black bars). These
results explain, at least in part, the phenotype of the two
patients studied in this work.
Discussion
Here we describe a new mutation in the TITF1/NKX2.1
gene in two sisters affected by choreoathetosis and hypo-
thyroidism but without respiratory distress. The fact that
both patients were correctly treated with levothyroxine sug-
gests that the neurological problems are related to gene im-
pairment in the brain rather than a consequence of hypo-
thyroidism. Homozygous mutations of this gene in humans
have not been described, probably due to the lethal effect of
these abnormalities. The two sisters studied here have a
heterozygous point mutation in the gene; we present func-
tional evidence that this deletion is responsible for the phe-
notype described. Family analysis indicated that the mother
carries the same mutation; she had mild and transient hy-
pothyroidism during gestation, but no choreoathetotic
movements were reported. If this is correct, the mother rep-
resents the first case described in which a TTF1 mutation
causes only thyroid alterations. Information provided by the
family indicated that the grandmother also had choreoath-
etotic movements during childhood that later disappeared;
no symptoms of hypothyroidism were reported, perhaps
because thyroid function was not studied at that time. The
variable phenotype in the family may be explained by dif-
ferences in modifier genes that produce a different genetic
background in a same family.
Since the first report of BHC (43), a large number of fam-
ilies have been reported with this condition, with consider-
able intra- and interfamilial phenotypic variation. The locus
wasmapped to chromosome 14q onwhich the humanTITF1/
NKX2.1 gene is located (27). This gene is composed of three
exons and produces two major transcripts (2.5 and 2.3 kb)
that encode proteins of 401 and 371 amino acids, respectively
(37, 38). The most active and abundant polypeptide is the
shorter isoform (371 amino acids), which translates from the
first ATG in the second exon (44). This isoform is encoded by
the wt vector used in this study (10), and the 825delC mu-
tation is based on this shorter transcript.
Mutations in this gene were recently described in patients
with CH having neurological and pulmonary problems (10–
14). The mutations occur in the DNA-binding domain (11,
12), the N-terminal domain (10, 11) or intron 2 (13, 14). In all
cases, the DNA-binding domain is altered or missing with
parallel loss of functional activity, producing a reduction by
half in the TTF1 protein levels, a phenomenon known as
haploinsufficiency (45).
In the patients reported here, haploinsufficiency may also
be the mechanism involved because, although the mutation
is not in the DNA binding domain, it does generate a protein
that has lost its transactivation capacity. Furthermore, the
transfection data point to a tissue-specific dominant-negative
effect. In fact, it has been suggested that if a deletion changes
only the carboxy terminus of a transcription factor, the mut
may function as a poison protein, interferingwith the activity
of the wt protein (45).
To our knowledge, only one C-terminal domain mutation
has been described in TTF1 (12), which is a frameshift mu-
tation that results in an aberrant protein starting at codon 273
[named 303 by Breedveld et al. (12)], rather than 275; this
protein also lacked 22 amino acids. The patient had BHC,
although the status of respiratory and thyroid function was
not reported, and no functional assays were carried out.
We predicted the secondary structure of the nonsense
region generated in the mutated protein and compared it
with the wt protein. The SOPMA program (36) predicts a
secondary structure with a greatly altered C-terminal do-
main in the mutated protein (Fig. 8). The mut protein has
mainly a random coil structure, interrupted by a single helix
in a position that differs from that of wt TTF1. These data
were confirmed by several different secondary structure pre-
diction methods (46, 47). The properties of this structure
could affect DNA binding, transactivation, or protein-pro-
FIG. 6. Transcription activation by wt and mut TTF1 from the hTg enhancer/promoter (A), the hTPO promoter (B), and the hSP-B promoter
(C). Promoter constructs were cotransfected into HeLa cells with the empty pcDNA3 expression vector or the expression vector harboring wt
or mut TTF1 cDNA. The amounts and combinations used are indicated. Promoter activity is expressed as fold induction, relative to the activity
observed in the presence of empty expression vector; luciferase activity is normalized to Renilla activity derived from the cotransfected pRL-Tk
vector to adjust for transfection efficiency. Results are mean SD of four independent experiments. **, P 0.01; *, P 0.05. ns, Not significant.
hTg, Human Tg; hTPO, human TPO.
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tein interactions. We performed experiments to elucidate
which of the above properties is affected. Our results show
that the DNA binding capability of the mutated protein is
reduced and that it does not interfere with the DNA binding
of the wt protein. We show, however, that the mutated pro-
tein has a strong dominant-negative effect on transcription
from the Tg and TPO promoters but not from the SP-B
promoter. The differential effect may indicate that the mu-
tated protein impairs the interaction of wt TTF1 with differ-
ent activators or coactivators in thyroid but not in lung.
Actually, TTF1 interacts with various factors in a tissue-
specific manner, such as PAX8 and DREAM in thyroid (37,
48) and AP-1 family members, BR22, RARs, CBP/p300,
SRC-1, GATA-6, STAT-3, NF-1, and TAZ in lung (49–56).We
present preliminary evidence, using both the Tg and artificial
Gal4-binding-site promoters, that mutated TTF1 interferes
with the cooperative interaction betweenwt TTF1 and PAX8.
An intriguing question is why we observed the dominant-
negative effect on the Tg and TPO promoters in HeLa cells
that do not express PAX8. This observationmay indicate that
other proteins with a similar activity replace PAX8 function
in HeLa cells. Although additional experiments regarding
this issue remain to be performed, we believe that this piece
of information is of interest to understand the phenotype of
the two sisters studied in this work. Another possible ex-
planation for the differential role of themutatedTTF1 protein
in thyroid and lung may be related to the different archi-
tecture of the Tg, TPO (18, 57), or SP-B (29) promoters with
which TTF1 interacts. Because promoter sequences provide
a platform for a large number of direct or indirect proteins
interactions, the consequences of reduced binding of even
one transcription factor could be considerable. Besides, the
loss of one transactivation domain, two serines, necessary for
TTF1 phosphorylation (39), and one cysteine, involved in
TTF1 dimerization (40), may affect specific, complex mech-
anisms such as cell type-specific selection of target
promoters.
The neurologicalmechanisms responsible for BHC are still
poorly understood. This disease is caused by haploinsuffi-
ciency of the TTF1 protein. Inmouse brain, TTF1 is expressed
in the median ganglionic eminence, which gives rise to the
pallidal component of the basal ganglia. Consistent with this
expression pattern, TITF1/NKX2.1 null mice do not form the
pallidal structures due to ventral-to-dorsal transformation of
the pallidal primordium into a striatum-like structure (22,
58). These mice show an imbalance in the number of striatal
and pallidal neurons, which could be responsible for hy-
perkinesia (10) and choreoathetotic movements (11). In the
sisters studied here, the choreoathetotic phenotype can be
explained by the mutation reported; we speculate that an
increased number of striatal neurons could be the cause.
In conclusion, our functional data explain that the phe-
notype observed in two patientswith hypothyroidism but no
pulmonary distress is due to a deletion of cytosine 825 in
exon 3 of the TITF1/NKX2.1 gene. Experiments are nonethe-
less required to understand the role of the TITF1/NKX2.1
gene at the neurological level and clarify the mechanisms
involved in the choreoathetotic phenotype.
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